[Evaluation of induced hypertension chemotherapy (IHC) in ambulatory cancer patients].
To evaluate ambulatory cancer chemotherapy (ACC), the clinical response, dose intensity of anticancer drugs, toxicities, ambulatory periods (AP) and survival days (SD) were analysed among 20 outpatients with various types of advanced cancer who were continuously treated by angiotensin II-IHC for the past 10 years. ACC was assessed with a questionnaire by the patients themselves or their families. In advanced cancer, at first, it was essentially to obtain a get clinical response or to stabilize the condition for a while, and secondly, to upgrade the performance status in better grade. Although AP and SD were so differed with the individuals: AP/SD = 1692.2 +/- 1450.2 days/2075.0 +/- 1348.0 days for CR (n = 5); 1086.0 +/- 1160.2 days/1344.3 +/- 1143.7 days for PR (n = 10); and 197.3 +/- 129.2 days/471.7 +/- 362.5 days for PD (n = 3). Alopecia, nausea/vomiting and appetite loss were the most frequent side effects, though these were almost completely controllable by ACC. Patients and their families could be cooperated and allow receiving ACC. The key in fighting cancer is the formation of good human relationship between medical oncologists and patients (including their families) mutual confidence, and giving a sufficient explanation for therapies.